Cargando…
Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system
INTRODUCTION: We have evaluated the use of silica–dopamine reservoirs synthesized by the sol–gel approach with the aim of using them in the treatment of Parkinson’s disease, specifically as a device for the controlled release of dopamine in the striatum. Theoretical calculations illustrate that dopa...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025590/ https://www.ncbi.nlm.nih.gov/pubmed/21289978 http://dx.doi.org/10.2147/IJN.S13223 |
_version_ | 1782196931006562304 |
---|---|
author | López, Tessy Bata-García, José L Esquivel, Dulce Ortiz-Islas, Emma Gonzalez, Richard Ascencio, Jorge Quintana, Patricia Oskam, Gerko Álvarez-Cervera, Fernando J Heredia-López, Francisco J Góngora-Alfaro, José L |
author_facet | López, Tessy Bata-García, José L Esquivel, Dulce Ortiz-Islas, Emma Gonzalez, Richard Ascencio, Jorge Quintana, Patricia Oskam, Gerko Álvarez-Cervera, Fernando J Heredia-López, Francisco J Góngora-Alfaro, José L |
author_sort | López, Tessy |
collection | PubMed |
description | INTRODUCTION: We have evaluated the use of silica–dopamine reservoirs synthesized by the sol–gel approach with the aim of using them in the treatment of Parkinson’s disease, specifically as a device for the controlled release of dopamine in the striatum. Theoretical calculations illustrate that dopamine is expected to assume a planar structure and exhibit weak interactions with the silica surface. METHODS: Several samples were prepared by varying the wt% of dopamine added during the hydrolysis of tetraethyl orthosilicate. The silica–dopamine reservoirs were characterized by N(2) adsorption, scanning and transmission electron microscopy, and Fourier transform infrared spectroscopy. The in vitro release profiles were determined using ultraviolet visible absorbance spectroscopy. The textural analyses showed a maximum value for the surface area of 620 m(2)/g nanostructured silica materials. The stability of dopamine in the silica network was confirmed by infrared and (13)C-nuclear magnetic resonance spectroscopy. The reservoirs were evaluated by means of apomorphine-induced rotation behavior in hemiparkisonian rats. RESULTS: The in vitro dopamine delivery profiles indicate two regimes of release, a fast and sustained dopamine delivery was observed up to 24 hours, and after this time the rate of delivery became constant. Histologic analysis of formalin-fixed brains performed 24–32 weeks after reservoir implantation revealed that silica–dopamine implants had a reddish-brown color, suggesting the presence of oxidized dopamine, likely caused by the fixation procedure, while implants without dopamine were always translucent. CONCLUSION: The major finding of the study was that intrastriatal silica–dopamine implants reversed the rotational asymmetry induced by apomorphine, a dopamine agonist, in hemiparkinsonian rats. No dyskinesias or other motor abnormalities were observed in animals implanted with silica or silica–dopamine. |
format | Text |
id | pubmed-3025590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-30255902011-02-02 Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system López, Tessy Bata-García, José L Esquivel, Dulce Ortiz-Islas, Emma Gonzalez, Richard Ascencio, Jorge Quintana, Patricia Oskam, Gerko Álvarez-Cervera, Fernando J Heredia-López, Francisco J Góngora-Alfaro, José L Int J Nanomedicine Original Research INTRODUCTION: We have evaluated the use of silica–dopamine reservoirs synthesized by the sol–gel approach with the aim of using them in the treatment of Parkinson’s disease, specifically as a device for the controlled release of dopamine in the striatum. Theoretical calculations illustrate that dopamine is expected to assume a planar structure and exhibit weak interactions with the silica surface. METHODS: Several samples were prepared by varying the wt% of dopamine added during the hydrolysis of tetraethyl orthosilicate. The silica–dopamine reservoirs were characterized by N(2) adsorption, scanning and transmission electron microscopy, and Fourier transform infrared spectroscopy. The in vitro release profiles were determined using ultraviolet visible absorbance spectroscopy. The textural analyses showed a maximum value for the surface area of 620 m(2)/g nanostructured silica materials. The stability of dopamine in the silica network was confirmed by infrared and (13)C-nuclear magnetic resonance spectroscopy. The reservoirs were evaluated by means of apomorphine-induced rotation behavior in hemiparkisonian rats. RESULTS: The in vitro dopamine delivery profiles indicate two regimes of release, a fast and sustained dopamine delivery was observed up to 24 hours, and after this time the rate of delivery became constant. Histologic analysis of formalin-fixed brains performed 24–32 weeks after reservoir implantation revealed that silica–dopamine implants had a reddish-brown color, suggesting the presence of oxidized dopamine, likely caused by the fixation procedure, while implants without dopamine were always translucent. CONCLUSION: The major finding of the study was that intrastriatal silica–dopamine implants reversed the rotational asymmetry induced by apomorphine, a dopamine agonist, in hemiparkinsonian rats. No dyskinesias or other motor abnormalities were observed in animals implanted with silica or silica–dopamine. Dove Medical Press 2011 2010-12-16 /pmc/articles/PMC3025590/ /pubmed/21289978 http://dx.doi.org/10.2147/IJN.S13223 Text en © 2011 López et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research López, Tessy Bata-García, José L Esquivel, Dulce Ortiz-Islas, Emma Gonzalez, Richard Ascencio, Jorge Quintana, Patricia Oskam, Gerko Álvarez-Cervera, Fernando J Heredia-López, Francisco J Góngora-Alfaro, José L Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system |
title | Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system |
title_full | Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system |
title_fullStr | Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system |
title_full_unstemmed | Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system |
title_short | Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system |
title_sort | treatment of parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025590/ https://www.ncbi.nlm.nih.gov/pubmed/21289978 http://dx.doi.org/10.2147/IJN.S13223 |
work_keys_str_mv | AT lopeztessy treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem AT batagarciajosel treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem AT esquiveldulce treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem AT ortizislasemma treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem AT gonzalezrichard treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem AT ascenciojorge treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem AT quintanapatricia treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem AT oskamgerko treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem AT alvarezcerverafernandoj treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem AT heredialopezfranciscoj treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem AT gongoraalfarojosel treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem |